Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYROSAFE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYROSAFE.
POTASSIUM IODIDE vs THYROSAFE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium iodide suppresses thyroid hormone synthesis and release via the Wolff-Chaikoff effect, inhibiting iodide organification and reducing vascularity of the thyroid gland.
THYROSAFE is a thyroid hormone replacement therapy containing levothyroxine, a synthetic T4 hormone. It exerts its physiological effects by binding to thyroid hormone receptors (TRα and TRβ) in target tissues, modulating gene transcription and cellular metabolism.
Oral: 300 mg (0.3 mL of saturated solution) three times daily for thyroid protection in radiation exposure; for hyperthyroidism preoperative: 60-250 mg (0.06-0.25 mL) three times daily.
Initial: 0.075 mg orally once daily; adjust dose every 2-4 weeks based on TSH. Typical maintenance dose: 0.05-0.15 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateWarfarin + Potassium Iodide
"Warfarin may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenprocoumon + Potassium Iodide
"Phenprocoumon may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenindione + Potassium Iodide
"Phenindione may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderateAcenocoumarol + Potassium Iodide
Terminal half-life in euthyroid individuals is approximately 13 days (range 10–15 days). In hyperthyroidism, half-life may be shortened to 5–6 days due to increased thyroid clearance; in hypothyroidism, half-life may be prolonged up to 40 days.
Terminal elimination half-life is 12-18 hours (mean 15 hours). In hyperthyroidism, clearance may be increased; in renal impairment, half-life prolonged.
Renal: >90% of absorbed iodide is excreted in urine; fecal elimination is negligible (<2%).
Primarily renal (60-80%) as unchanged drug; 20-40% as glucuronide conjugates; minimal biliary/fecal (<5%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent
"Acenocoumarol may decrease the anticoagulant activities of Potassium Iodide."